Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10


BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors.

Rhyasen GW, Yao Y, Zhang J, Dulak A, Castriotta L, Jacques K, Zhao W, Gharahdaghi F, Hattersley MM, Lyne PD, Clark E, Zinda M, Fawell SE, Mills GB, Chen H.

PLoS One. 2018 Jul 23;13(7):e0200826. doi: 10.1371/journal.pone.0200826. eCollection 2018.


AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.

Rhyasen GW, Hattersley MM, Yao Y, Dulak A, Wang W, Petteruti P, Dale IL, Boiko S, Cheung T, Zhang J, Wen S, Castriotta L, Lawson D, Collins M, Bao L, Ahdesmaki MJ, Walker G, O'Connor G, Yeh TC, Rabow AA, Dry JR, Reimer C, Lyne P, Mills GB, Fawell SE, Waring MJ, Zinda M, Clark E, Chen H.

Mol Cancer Ther. 2016 Nov;15(11):2563-2574. Epub 2016 Aug 29.


Modeling de novo leukemogenesis from human cord blood with MN1 and NUP98HOXD13.

Imren S, Heuser M, Gasparetto M, Beer PA, Norddahl GL, Xiang P, Chen L, Berg T, Rhyasen GW, Rosten P, Park G, Moon Y, Weng AP, Eaves CJ, Humphries RK.

Blood. 2014 Dec 4;124(24):3608-12. doi: 10.1182/blood-2014-04-564666. Epub 2014 Oct 22.


IRAK signalling in cancer.

Rhyasen GW, Starczynowski DT.

Br J Cancer. 2015 Jan 20;112(2):232-7. doi: 10.1038/bjc.2014.513. Epub 2014 Oct 7. Review.


OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues.

Wunderlich M, Brooks RA, Panchal R, Rhyasen GW, Danet-Desnoyers G, Mulloy JC.

Blood. 2014 Jun 12;123(24):e134-44. doi: 10.1182/blood-2014-02-556340. Epub 2014 Apr 28.


An MDS xenograft model utilizing a patient-derived cell line.

Rhyasen GW, Wunderlich M, Tohyama K, Garcia-Manero G, Mulloy JC, Starczynowski DT.

Leukemia. 2014 May;28(5):1142-5. doi: 10.1038/leu.2013.372. Epub 2013 Dec 11. No abstract available.


Differential IRAK signaling in hematologic malignancies.

Rhyasen GW, Bolanos L, Starczynowski DT.

Exp Hematol. 2013 Dec;41(12):1005-7. doi: 10.1016/j.exphem.2013.09.008. Epub 2013 Sep 29. No abstract available.


Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.

Rhyasen GW, Bolanos L, Fang J, Jerez A, Wunderlich M, Rigolino C, Mathews L, Ferrer M, Southall N, Guha R, Keller J, Thomas C, Beverly LJ, Cortelezzi A, Oliva EN, Cuzzola M, Maciejewski JP, Mulloy JC, Starczynowski DT.

Cancer Cell. 2013 Jul 8;24(1):90-104. doi: 10.1016/j.ccr.2013.05.006.


Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.

Fang J, Rhyasen G, Bolanos L, Rasch C, Varney M, Wunderlich M, Goyama S, Jansen G, Cloos J, Rigolino C, Cortelezzi A, Mulloy JC, Oliva EN, Cuzzola M, Starczynowski DT.

Blood. 2012 Jul 26;120(4):858-67. doi: 10.1182/blood-2012-02-407999. Epub 2012 Jun 8. Erratum in: Blood. 2014 Jun 5;123(23):3682.


Deregulation of microRNAs in myelodysplastic syndrome.

Rhyasen GW, Starczynowski DT.

Leukemia. 2012 Jan;26(1):13-22. doi: 10.1038/leu.2011.221. Epub 2011 Aug 19. Review.


Supplemental Content

Loading ...
Support Center